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presence of EGFR mutations (odds ratio, 0.019; 95% CI, 0.001-0.298; 
P=0.005) was signiﬁcantly associated with the higher response rate to 
geﬁtinib. Progression-free survival (6.6 vs. 3.3 months; p=0.246) and 
overall survival (8.1 vs. 8.6 months; p=0.397) were similar between 
patients with EGFR mutations and those with wild-type EGFR.
Conclusion: Clinical response to geﬁtinib in this study was linked to 
the presence of EGFR mutations. Given the limitation of small sample 
size, EGFR mutations were not associated with the speciﬁc clinical 
predictors for geﬁtinib responsiveness.
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Background: Retrospective analyses of previous trials have shown the 
clinical advantage of geﬁtinib in advanced non-small cell lung cancer 
(NSCLC) patients with certain favorable baseline factors (Asian ethnic-
ity, female, adenocarcinoma, or no smoking history). This prospective 
phase II study was designed to test the hypothesis that higher response 
rates might be achieved if patients are selected according to these clini-
cal predictors for response.
Methods: Korean NSCLC patients who have failed after docetaxel-
based ﬁrst-line chemotherapy were consecutively accrued. Patients 
without any of the favorable clinical predictors (i.e., male smoker with 
non-adenocarcinoma) received irinotecan 100 mg/m2 on days 1, 8 and 
15 every 4 weeks (irinotecan arm). Patients who had at least one of the 
predictors for response received geﬁtinib 250 mg/d orally from day 1 
(geﬁtinib arm). Primary endpoint was response rate. With a two-stage 
phase II design, the required number of patients was at least 25 per 
each arm.
Results: Of 68 patients accrued, 25 were treated with irinotecan and 
43 with geﬁtinib. In the geﬁtinib arm, 22 patients were female, 20 were 
never-smoker, and 33 had adenocarcinoma. Treatment duration was 
signiﬁcantly longer in the geﬁtinib arm (2.0 months for irinotecan arm 
v 3.9 months for geﬁtinib arm; p<0.01). Median number of chemother-
apy cycles was 2 (range, 1-6) for irinotecan arm. Fewer drug-related 
toxicities were observed with geﬁtinib compared with irinotecan. In 
the irinotecan and geﬁtinib arm, 36% and 9% of patients, respectively, 
discontinued treatment because of toxicity. The objective responses of 
irinotecan and geﬁtinib arm were 16% (95% CI, 2-30) and 40% (95% 
CI, 25-54), respectively (p=0.04). Patients in the geﬁtinib arm had a 
longer (p=0.04), progression-free survival (5.3 months; 95% CI, 1.7-
8.8) than those in the irinotecan arm (3.2 months; 95% CI, 1.7-4.6).
Conclusion: Geﬁtinib could be a reasonable second-line option in Ko-
rean NSCLC patients who had at least one favorable clinical predictor.
P3-130 NSCLC: Molecular Targeted Therapy Posters, Wed, Sept 5 – Thurs, Sept 6 
A large Spanish experience with erlotinib in advanced non-small 
cell lung cancer
Paz-Ares, Luis1 González-Larriba, José-Luis2 Viñolas, Nùria3 Arízcum, 
Alberto4 Gutiérrez-Abad, David5 Madroñal, Caterina6 Delgado, José 
Ramón7 Martínez Del Prado, Puriﬁcación8 Amador, Maria Luz9 
Massutí, Bartomeu10 
1 Hospital Universitario 12 de Octubre, Madrid, Spain 2 Hospital Clíni-
co San Carlos, Madrid, Spain 3 CSC-Hospital Clínic, Barcelona, Spain 
4 Hospital General Río Carrión, Palencia, Spain 5 Hospital Ntra. Sra. 
de Sonsoles, Ávila, Spain 6 Institut d’Oncologia Corachán, Barcelona, 
Spain 7 Hospital Universitario Virgen de las Nieves, Granada, Spain 8 
Hospital de Basurto, Bilbao, Spain 9 Roche Farma, S.A., Madrid, Spain 
10 Hospital General Universitario de Alicante, Alicante, Spain 
Background: Erlotinib is an orally active and selective inhibitor of 
HER1/EGFR tyrosine kinase, which gained approval for the treat-
ment of previously treated patients with advanced non-small cell lung 
cancer (NSCLC). The randomized, phase III study BR.21 demonstrated 
a signiﬁcant survival beneﬁt for patients with advanced NSCLC who 
received erlotinib versus placebo (HR: 0.70, 95% CI 0.58–0.85), after 
failure to one or more previous treatments. The TargeT trial is a large, 
Spanish, non-randomized, phase II trial evaluating the efﬁcacy and 
safety of erlotinib in patients with advanced or metastatic NSCLC.
Methods: Patients with previously treated advanced or metastatic 
NSCLC or patients that were not suitable for ﬁrst line conventional 
chemotherapy, stage IIIB/IV, PS 0-2 were enrolled to receive oral erlo-
tinib 150 mg/day until disease progression or withdrawal. The primary 
endpoint of the study was time to progression (TTP) in the intent to 
treat (ITT) population. 
Results: 1,796 patients were enrolled from June 04 to March 06 and 
1,539 evaluated for this analysis. Demographics: median age 65 y 
[range 26–95]; male: 72%; stage IV: 82%; PS 0/1/2: 21%/54%/25%; 
adenocarcinoma histology: 53%, SCC: 25.0%, LCC: 16%, other: 6%; 
current/former smoker: 78%. Patients receiving erlotinib as 1st/2nd/
≥3rd line were 29%/39%/33%, respectively. 879 were analyzed for 
response: 11 patients reached CR (1%), 154 PR (18%), for and overall 
response rate of 19%. Control disease rate was 58%.
In the exploratory subgroup analysis, higher response rate (RR) was 
related to female gender (35.9% vs. 11.1%; p<0.0001), the absence 
of smoking habits (42.2% vs. 11.7%; p<0.0001) and adenocarcinoma 
histology (25.8 vs. 11.4; p<0.0001). Patients receiving erlotinib in the 
ﬁrst line setting reached signiﬁcantly higher RRs (31.5%) than in fur-
ther lines of treatment (13.8%; p<0.0001). All these factors remained 
as predictive factors for response in the multivariate analysis, with 
the exception of gender. Similar results were found regarding control 
disease rate. 
In the ITT population, median time to progression was 3.9 months 
[95% CI 3.5–4.4] and median overall survival 6.1 months [95% CI 
5.5–6.4 months]. Statistically signiﬁcant differences were found in 
favor of nonsmokers (TTP and OS: p<0.0001), patients with a good 
performance status (TTP: p=0.004; OS: p<0.0001) and adenocarcinoma 
(for the comparison with other grouped histologies; TTP: p=0.002; 
OS: p<0.0001), both in the univariate and multivariate analysis (p 
refers to the latter analysis). Interestingly, no differences between 
adenocarcinoma and SCC speciﬁcally were detected. Treatment in the 
ﬁrst line setting was also associated with longer TTP in the Cox model 
(P=0.002), but not with longer survival. Finally, female gender did not 
signiﬁcantly associate with TTP or survival.
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As expected, rash and diarrhea were the most frequent adverse events. 
Conclusions: This interim analysis in a very large, unselected popula-
tion with advanced NSCLC in a real-practice clinical setting conﬁrms 
that erlotinib is active and well tolerated in patients with advanced 
NSCLC untreated or that have previously failed to conventional 
chemotherapy. Our data indicate that good performance status and non 
smoking history are the most convincing predictive factors for a longer 
TTP and survival in patients treated with erlotinib.
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Background: In NSCLS patients, deletions in EGFR exon 19 are 
associated with higher response rate and prolonged survival. K-ras 
substitutions in Exon 1, originally understood as mutually exclusive to 
EGFR mutations, are known as negative prognostic factor for survival 
and negative predictor of EGFR tyrosinkinase inhibitors efﬁcacy in 
NSCLC. The aim of this work was to conﬁrm above assumptions on a 
group of Czech NSCLC patients. 
Material and Methods: Cytologic and/or histologic tissue specimens 
taken from NSCLC patients treated by geﬁtinib in Early Access Pro-
gramme in Czech Republic, were processed by laser microdissection 
and screened for presence of K-ras mutations in codons 12 and 13 and 
EGFR mutations in exon 19. Therapy response and survival was corel-
lated to patients EGFR and K-ras mutation status.
Results: K-ras mutations were found in 28/252 examined patients, 
EGFR deletions in exon 19 were found in 24/279 patients. Addition-
ally, simultaneous occurence of the two mutations was detected in two 
tumour samples. The objective response to geﬁtinib was signiﬁcantly 
higher in patients with EGFR mutated tumours compared to none muta-
tion or k-ras positive status (42.8% vs 10% vs 4%). Median survival in 
EGFR mutated patients was 440 days, in patients without any mutation 
194 days and 156 days in k-ras mutated patients. The two patients har-
bouring both EGFR and k-ras mutations survived 174 and 259 days. At 
3 months from the start of geﬁtinib therapy 90% of the EFGR mutated 
patients were surviving, while 77% from non-mutated and only 57% of 
k-ras mutated. At 24 months from therapy, 15% of EGFR positive pa-
tients were surviving, 4% from k-ras and 3% from non-mutated group.
Conclusions: EGFR mutated tumours show overall better response to 
tyrosinkinase inhibitors compared to any other mutation type. K-ras 
positive patients exhibited very poor response and low survival within 
the ﬁrst 3 - 6 month of the therapy compared to non-mutated patients. 
In the long-term, however, the survival was no longer affected by the 
k-ras mutation presence. Simultaneous occurence of both, EGFR and 
k-ras mutations, was detected, but the incidence is very rare.
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Objectives: Previous studies have shown acceptable toxicity and en-
couraging activity for the combination of docetaxel (D) with oxaliplatin 
(Ox) in NSCLC. This study aims to speciﬁcally determine safety and 
efﬁcacy of this novel taxane/platinum doublet with bevacizumab (Bev), 
as ﬁrst-line treatment of advanced or recurrent and/or metastatic in che-
motherapy-naïve pts with NSCLC. We hereby report initial safety data.
Methods: The regimen to be delivered in eligible patients is as follows: 
6 cycles of D (70 mg/m2), Ox (100 mg/m2), and Bev (15 mg/kg) Q3W, 
followed by single-agent Bev (15 mg/kg) Q3w (until completion of one 
year of therapy). Patients continue treatment until evidence of disease 
progression, unacceptable toxicity, prolonged treatment delay, patient 
refusal to continue on study, or death.
Results: 25 pts (>18y) have been enrolled to-date; however, we are 
reporting information only on 14 pts, who have completed at least 2 
cycles (cy.) of therapy, and in whom complete demographic, safety, 
and other data exist at the time of this analysis. Distribution of disease 
stages (S) was: SIIIB: 2 pts (14.3%) and SIV: 12 pts (85.7%). ECOG 
PS distribution was: 0 in 10 pts, and 1 in 4 pts; there were no pts with 
PS>1. There were 2/14 (14.3%) female pts. Median age was 61.0 yrs; 
9 pts (64.3%) were < 65 yrs old. Full dose of agents were delivered in: 
12/14 pts for D and Ox, and 14/14 pts for Bev. No dose delays were ob-
served for any agent. A total of 33 cycles (cy.) were administered: 4 cy. 
in 2 pts, 3 cy. in 1 pt, and 2 cy. in 11 pts. Mean number of cy. complet-
ed was 2.4. The most frequently (>22% of pts) reported adverse events 
(AE’s) of any grade were: pain (64.3%); asthenia (57.1%); dysgeusia 
(50%); skin-related AE’s (rash or ﬂushing) (42.9%), as well as diarrhea, 
nausea, anorexia, and vomiting (35.7% each). Fourteen grade (G) 3/4 
AE’s were seen in 7 pts, including neutropenia: 4 (of which 1 was 
febrile), pneumonia: 2, sepsis: 1, GI AE’s: 4, hypertension: 1, fatigue: 
1, and broncho-esophageal ﬁstula: 1. Eight of the 14 G3/4 AE’s were 
severe (SAE’s) and occurred in 3 pts. There were 2 deaths, one due to 
disease progression, and another one due to a SAE (possibly drug-
related), occurring within 91 and 35 days from completion of the 2nd 
cy. of Rx, respectively. Of note, despite the above G3/4 AE and SAE 
proﬁles, only 2 pts required dose modiﬁcation for D or Ox, while no 
pts experienced dosing delays. Furthermore, to-date, no Bev-associated 
colonic perforations or pulmonary hemorrhages have been reported.
Conclusions: These preliminary data support feasibility of this regi-
men, as they show acceptable safety features, and will be updated at 
the time of presentation. The plan is to continue enrollment to 75 pts. 
Primary efﬁcacy endpoint is progression-free survival, while secondary 
endpoints are objective response rate and overall survival. 
N.B.: This study is sponsored by Sanoﬁ-Aventis. 
